-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
March 8, 2022 / Bio Valley BIOON/--- Interleukin-2 (IL-2) is a crucial T cell cytokine that promotes T cell proliferation and effector function, and is considered a therapeutic a method for cancer; however, systemic administration of IL-2 often results in severe toxic side effects, which limits its application in enhancing CAR-T cell immunotherapy
In a new study, researchers from the Perelman School of Medicine at the University of Pennsylvania and the Stanford University School of Medicine designed a pair of human orthogonal IL-2 (ortho-hIL-2) and human Orthogonal IL-2Rβ (ortho-hIL-2Rβ) pair containing human-specific mutations
T cells, image via CC0 Public Domain
T cells are genetically engineered to express the receptor ortho-hIL-2Rβ, which can only be activated by ortho-hIL-2
Using CAR-T cells that specifically target CD19, these authors found that ortho-hIL-2 induced ortho-hIL-2Rβ-positive CAR-T cells 2 weeks after adoptive transfer into immunodeficient mice bearing CD19+ Nalm6 leukemia xenografts Dose-dependent increase of T cell proliferation in vivo by up to 1000-fold
Ortho-hIL-2 can rescue the anti-leukemia effect of an unsatisfactory CAR-T cell dose
References:
Qian Zhang et al.